LanguaTalk

Surfing the MASH Tsunami

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

S3-E44.3 - Anticipating the Aftermath: Previewing Outcomes of Paris NASH

13 mins; September 10, 2022

S3-E44.2 - Highlights from Paris NASH and an Integrated Multi-Specialty Approach

13 mins; September 10, 2022

S3-E44.1 - Paris NASH Meeting Preview: Program Highlights on Metabolics

14 mins; September 10, 2022

S3-E44 - A Preview of Paris NASH and NAFLD Summit 2022

63 hours 25 mins; September 07, 2022

From the Vault: Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs

96 hours 26 mins; September 04, 2022

S3-E43.5 - The Future of Combination Agents in NASH Therapy

10 mins; September 04, 2022

S3-E43.4 - Optimizing Combination Agents

12 mins; September 04, 2022

S3-E43.3 - Science Partnerships and NASH Trials

13 mins; September 03, 2022

S3-E43.2 - Finding the Right Combinations in NASH Therapy

12 mins; September 03, 2022

S3-E43.1 - Combination Agents for Fibrotic Regression

14 mins; September 03, 2022

S3-E43 - Combination Agents: a Cornerstone Of Future NASH Therapy?

63 hours 21 mins; August 31, 2022

S3-E42.5 - From the Vault: NASH Patient Care and the Value of Patient Education

21 mins; August 28, 2022

S3-E42.4 - Allied Health and Patient Empowerment for NAFLD

14 mins; August 28, 2022

S3-E42.3 - Allied Health and Patient Empowerment for NAFLD

13 mins; August 27, 2022

S3-E42.2 - Allied Health and Patient Empowerment for NAFLD

15 mins; August 27, 2022

S3-E42.1 - Allied Health and Patient Empowerment for NAFLD

17 mins; August 27, 2022

S3-E42 — Allied Health and Patient Empowerment for NAFLD

64 hours 19 mins; August 24, 2022

S3-E41.6 - From the Vault: Why NASH Drug Trials Fail

17 mins; August 21, 2022

S3-E41.5 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

12 mins; August 21, 2022

S3-E41.4 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

12 mins; August 21, 2022

S3-E41.3 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

12 mins; August 20, 2022

S3-E41.2 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

13 mins; August 20, 2022

S3-E41.1 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

12 mins; August 20, 2022

S3-E41- Improving NASH Clinical Trials By Reducing Screen Fail Rates

63 hours 19 mins; August 17, 2022

S3-E40.5 - From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy

54 mins; August 14, 2022

S3-E40.4 - Challenges of Alcohol Screening in Fatty Liver Disease

13 mins; August 14, 2022

S3-E40.3 - Importance of Early Diagnosis in Lean NASH

12 mins; August 13, 2022

S3-E40.2 - A Simple Diagnostic Algorithm for Lean NASH

13 mins; August 13, 2022

S3-E40.1 - Best Practices in Lean NASH: How the Article Came About

12 mins; August 13, 2022

S3-E40 - Best Practices in Lean NASH -- Authors Provide Back Story

52 mins; August 10, 2022

S3-E39.5 - From The Vault: Early, Accurate Patient Information Matters

28 mins; August 07, 2022

S3-E39.4 - Patient Follow-Up Challenges in Modeling NASH Diagnostics

17 mins; August 07, 2022

S3-E39.3 - NASH challenges: Early Diagnosis and NASH Patient Management

14 mins; August 06, 2022

S3-E39.2 - What An Early Decision Models Tells Us About Fibrosis & Metabolic Diseases

13 mins; August 06, 2022

S3-E39.1 - Creating An Early Diagnosis NASH Decision Model

12 mins; August 06, 2022

S3-E39 - Reviewing a Decision Model for Early NASH Diagnosis

63 hours 24 mins; August 03, 2022

S3-E38.8 - From the Vault: Discussing Patient empowerment at INCBCN 2022

18 mins; July 31, 2022

S3-E38.7 - From the Vault: How Ballooned hepatocyte Reads Affect NASH Clinical Trials

18 mins; July 31, 2022

S3-E38.6 - From the Vault: Patient-Focused Drug Development from Global Liver Institute

19 mins; July 31, 2022

S3-E38.5 - From the Vault: NAIL-NIT tackles NAS Score Challenges

16 mins; July 30, 2022

S3-E38.4 - From the Vault: NITs & Advancing NASH Therapy at AASLD 2021

20 mins; July 30, 2022

S3-E38.3 - From the Vault: Learning About Stellate Cells and Fibrosis at Paris NASH

15 mins; July 30, 2022

S3-E38.2 - From the Vault: Scott Friedman on Fibrosis and Precision Medicine

57 mins; July 30, 2022

S3-E38.1 - From the Vault: Why NASH Drug Trials Fail

60 hours 29 mins; July 28, 2022

S3-E38 - SurfingNASH 2nd Anniversary: Buzzsprout, Download Barriers and More!

40 mins; July 27, 2022

S3-E37.5 - The Need to Focus on NASH Cirrhosis Patients

10 mins; July 24, 2022

S3-E37.4 - The "Pincer Movement" In Cirrhosis Technology: Patient Support vs High-End MedTech

11 mins; July 24, 2022

S3-E37.3 - Where Is The Next Cirrhosis Breakthrough?

12 mins; July 23, 2022

S3-E37.2 - Can Today's Medicines Cause Fibrosis Regression in Cirrhosis Patients?

11 mins; July 23, 2022

S3-E37.1 - Cirrhosis Screening & Diagnostic Tests

9 mins; July 23, 2022

S3-E37 - What Do We Know That Can Help NASH Cirrhosis Patients Today?

55 mins; July 20, 2022

S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?

13 mins; July 17, 2022

S3-E36.4 - REGENERATE Redux: Other Obeticholic Acid (OCA) Questions

12 mins; July 17, 2022

S3-E36.3 - REGENERATE Redux: Safety and Tolerability With Obeticholic Acid

12 mins; July 16, 2022

S3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For Patients

14 mins; July 16, 2022

S3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) Efficacy

13 mins; July 16, 2022

S3-E36 - REGENERATE Redux - Can OCA Succeed With New Data?

57 mins; July 13, 2022

S3-E35.5 - Liver Science At #ILC2022: Mid-Range Impact of Advances

11 mins; July 10, 2022

S3-E35.4 - Liver Science At #ILC2022: Commercial Benefits From the New Liver Science

12 mins; July 10, 2022

S3-E35.3 - Liver Science At #ILC2022: Stellate Cells, Omics and Novel Receptor Targets

11 mins; July 09, 2022

S3-E35.2 - Liver Science At #ILC2022: The Interplay of Stellate Cell Dynamics and Hepatic Fibrosis

15 mins; July 09, 2022

S3-E35.1 - Liver Science at #ILC2022: Circadian Rhythm and Stellate Cells

17 mins; July 09, 2022

S3-E35 - #ILC2022 Look Back: Liver Science and Fibrosis

64 hours 22 mins; July 06, 2022

S3-E32.3 - #ILC2022 Looking Back: NASH Is a Complex Disease

14 mins; July 04, 2022

S3-E32.2 - #ILC2022 Looking Back: NAFLD and Quality-of-Life

13 mins; July 04, 2022

S3-E32.1 - #ILC2022 Looking Back: Patient Motivation and Systems Incentives

20 mins; July 04, 2022

S3-E34.4 - #ILC2022 looking back: Crystal Balling and The Semaglutide Trial

11 mins; July 03, 2022

S3-E33.2 - #ILC2022 Looking Back: Patient Engagement 2 -- Patient Communication

16 mins; July 03, 2022

S3-E33.1 - #ILC2022 Looking Back: Patient Engagement 1 -- Nurses and Touchy Topics

13 mins; July 03, 2022

S3-E34.3 - #ILC2022 Looking Back: Early Pemvidutide Results and a Little More on FIB-4

12 mins; July 02, 2022

S3-E34.2 - #ILC2022 Looking Back: Other Thoughts on Resmetirom Presentations

11 mins; July 02, 2022

S3-E34.1 - #ILC2022 Looking Back: Resmetirom Late-Breaker and Cirrhosis Study

13 mins; July 02, 2022

S3-E34 #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!

59 mins; June 29, 2022

S3-E33 - Day 4 of ILC2022: Friendly Debates About NITs, PLUS Discussing the Patient Advocate's Perspective

50 mins; June 27, 2022

S3-E32 - Days 1-3 of ILC 2022: The Value of FIB-4 and In-Person Meetings

61 hours 43 mins; June 26, 2022

S3-E30.4 - Highlighting Intriguing #ILC2022 Abstracts: Potential Uses of FIB-4

15 mins; June 19, 2022

S3-E30.3 - Highlighting Intriguing #ILC2022 Abstracts: More on NAFLD Quality of Life

10 mins; June 19, 2022

S3-E30.2 - Highlighting Intriguing #ILC2022 Abstracts: Elastography and the Importance of NAFLD Quality-of-Life Metrics

15 mins; June 18, 2022

S3-E30.1 - Highlighting Intriguing #ILC2022 Abstracts: Machine Learning Identified NASH Biomarkers and a Cost-Effectiveness Study

16 mins; June 18, 2022

S3-E30 - Previewing #ILC2022: Focus on NITs and Patients

58 mins; June 15, 2022

S3-E29.2 - #NASHDay 2022 Wrap-Up Panel: The Importance of #StopNASHNow

15 mins; June 12, 2022

S3-E29.1 - #NASHDay 2022 Wrap-up Panel: What #NASHDay Means To Our Community In 2022 and Why It Matters

15 mins; June 12, 2022

S3-E28.4 - #NASHDay 2022 Preview: SurfingNASH Predictions

11 mins; June 12, 2022

S3-E28.3 - #NASHDay 2022 Preview: Exciting NASH Community Collaboration and How It Drives Us Forward

9 mins; June 11, 2022

S3-E28.2 - #NASHDay 2022 Preview: What New Approaches To Clinical Trial Design Will Mean For Our Community

12 mins; June 11, 2022

S3-E28.1 - #NASHDay 2022 Preview: New Approaches To Clinical Trial Design

13 mins; June 11, 2022

S3-E29 - #NASHDay 2022: SurfingNASH Wrap-up

61 hours 7 mins; June 09, 2022

S3-E28 - Previewing #NASHDay 2022: Patient Advocacy Thrives!

53 mins; June 08, 2022

S3-E27.6 - 5th Global NASH Congress Wrap-Up: Dual Weight Loss Agonists, Expanded Imaging and the Implications for NAFLD

17 mins; June 05, 2022

S3-E27.5 - 5th Global NASH Congress Wrap-Up: NAFLD Screening in Primary Care Practices With The GRIP Program

13 mins; June 05, 2022

S3-E27.4 - 5th Global NASH Congress Wrap-Up: An Interview with Becky Taub

23 mins; June 05, 2022

S3-E27.3 - 5th Global NASH Congress Wrap-Up: Key NAFLD Topics In The Room

15 mins; June 04, 2022

S3-E27.2 - 5th Global NASH Congress Wrap-Up: Quality-of-Life and Portable Liver Scans

13 mins; June 04, 2022

S3-E27.1 - 5th Global NASH Congress Wrap-Up: Fatty Liver Science and Patient Advocacy

14 mins; June 04, 2022

S3-E27 - 5th Global NASH Congress Wrap-Up: Highlights & Speaker Interviews

58 mins; June 01, 2022

S3-E26.4 - Advancing NASH Best Practices In NITs: Answering Questions, Next Steps

13 mins; May 29, 2022

S3-E26.3 - Advancing NASH Best Practices In NITs: Optimizing a NASH Biomarker Set

13 mins; May 29, 2022

S3-E26.2 - Advancing NASH Best Practices In NITs: "Stacking" NASH Biomarkers

14 mins; May 28, 2022

S3-E26.1 - Advancing NASH Best Practices In NITs: Quentin Anstee's Five Key Takeaways

14 mins; May 28, 2022

S3-E26 - What Are We Learning About Clinical Trial Best Practices For NITs?

55 mins; May 25, 2022

Click here to see more

Surfing the MASH Tsunami

Useful pages

Find a tutor

Languages